Stéphane Ciblat

This inventor holds 5 USPTO granted patents and 8 published patent applications and 2 EPO patents. Top assignees: Ventus Therapeutics U.s., Inc., Bhi Limited Partnership. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stéphane Ciblat. Retrieved from https://idiyas.com/inventor/stéphane-ciblat

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 8)

% Patents Active = 100.0

EPO Patents = 2 (Patent Applications = 10)

Average Co-Inventor Count = 2.9

ph-index = 1

Forward Citations = 13(Granted Patents)

Company Filing History:

4 out of 13

Ventus Therapeutics U.s., Inc.

patents

1 out of 5

Bhi Limited Partnership

patents

Years Active: 2014-2025

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410167 - Pyridazine compounds for inhibiting NLRP3 (2025-09-09),

2. 12398136 - Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors (2025-08-26),

3. 12331048 - Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors (2025-06-17),

4. 12312351 - Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors (2025-05-27),

5. 8748656 - Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (2014-06-10),

Title: Stéphane Ciblat: Innovator in NLRP3 Inhibition

Introduction

Stéphane Ciblat is a notable inventor based in Montreal, Canada. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit the NLRP3 protein. With a total of 5 patents to his name, Ciblat's work is paving the way for new treatments for various diseases.

Latest Patents

Ciblat's latest patents include innovative pyridazine compounds designed for inhibiting NLRP3. These compounds are useful in treating diseases and disorders associated with this protein. His disclosures detail the chemical structures and formulations of these inhibitors, including pyrido-[3,4-d]pyridazine amine derivatives, which are also aimed at providing therapeutic benefits.

Career Highlights

Throughout his career, Ciblat has worked with several prominent companies, including Ventus Therapeutics and BHI Limited Partnership. His expertise in drug development and molecular design has been instrumental in advancing research in the pharmaceutical industry.

Collaborations

Ciblat has collaborated with notable professionals in his field, including Stéphane Dorich and Xianqi Kong. These partnerships have enhanced his research and contributed to the successful development of his patented compounds.

Conclusion

Stéphane Ciblat is a distinguished inventor whose work in NLRP3 inhibition is making a significant impact in the medical field. His innovative patents and collaborations reflect his commitment to advancing healthcare solutions.

Profile summary based on public USPTO records.